phrykt

Drugs Made In America Acquisition Corp. (DMAA): who owns it and who trades it

As of Oct 30, 2026, no open-market insider purchases or sales of DMAA were reported in the last 12 months.

Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who owns DMAA

23 funds and institutions reported DMAA shares worth $146M at the end of Q2 2026, about 41% of the company. The largest holder is Mizuho Securities USA LLC with 12.1%.

Funds and institutions (13F) 41%Everyone else 59%

10 largest owners, by share of the company

Mizuho Securities USA LLC12.1%
Karpus Management, Inc.7.4%
Polar Asset Management Partners Inc.3.4%
Glazer Capital, LLC3.0%
Wolverine Asset Management LLC2.5%
Highbridge Capital Management LLC2.4%
First Trust Capital Management L.P.2.3%
Heights Capital Management, Inc1.9%
Westchester Capital Management, LLC1.7%
Clear Street Group Inc.1.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Mizuho Securities USA LLC4.07M12.07%$42.8M+103%
Karpus Management, Inc.2.51M7.44%$26.7M-1%
Polar Asset Management Partners Inc.1.15M3.40%$12.2M-28%
Glazer Capital, LLC999,8992.97%$10.6M-40%
Wolverine Asset Management LLC832,0932.47%$8.9M-46%
Highbridge Capital Management LLC809,0542.40%$8.6M-39%
First Trust Capital Management L.P.786,4592.33%$8.4M-65%
Heights Capital Management, Inc648,0831.92%$6.9M-0%
Westchester Capital Management, LLC581,7901.73%$6.2M-65%
Clear Street Group Inc.382,4401.13%$1.6M+8%
Aristeia Capital, L.l.c.350,0001.04%$3.7M-60%
Sona Asset Management (us) LLC162,7950.48%$1.7MNo change
RLH Capital LLC115,6060.34%$1.2M-63%
Logan Stone Capital, LLC109,9590.33%$1.2MNew
Toronto Dominion Bank100,0000.30%$1.1M-51%
Meteora Capital, LLC97,8370.29%$1M-74%
Quarry LP65,5510.19%$698K-75%
Geode Capital Management, LLC62,2730.18%$663KNo change
JPMorgan Chase & Co49,8910.15%$531K-96%
Dakota Wealth Management36,4000.11%$388KNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No DMAA insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

DMAA short interest

Low short interest. 0.4% of DMAA shares are sold short: about 1 share in 284. Over the last 12 reports the number of shares short went down 11%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 85,523 DMAA shares were sold short, 0.4% of the shares outstanding, down 4.0% from the report before. At the average daily volume of 17,289 shares, buying them all back would take about 5.0 trading days (days to cover).

Shares short, % of all shares

0.35%May 15Oct 300.40%

Days to cover

5.0May 15Oct 30179.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202685,5230.35%-4%17,2895.0
Oct 15, 202689,0880.37%-1%10,6998.3
Sep 30, 202689,7870.37%-3%889101.0
Sep 15, 202692,5230.38%+17%70,5101.3
Aug 31, 202679,3920.33%-1%15,7495.0
Aug 14, 202680,5950.33%-9%517155.9
Jul 31, 202688,6550.26%-6%17,3955.1
Jul 15, 202693,8940.28%+13%60,1381.6
Jun 30, 202682,9890.25%+8%35,8692.3
Jun 15, 202676,5320.23%-12%36,0482.1
May 29, 202686,9500.26%-10%58,5161.5
May 15, 202696,5070.29%-7%7,38413.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Drugs Made In America Acquisition company events

Drugs Made In America Acquisition filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 21, 2026.

  1. Oct 21, 2026AgreementDrugs Made In America Acquisition Corp. and Power Analytics Global Corp, a Delaware corporation, entered into Amendment No. 1 to their Amended and Restated Definitive Merger Agreement dated as of September 8, 2026. Filing
  2. Sep 14, 2026AgreementBackground As previously disclosed, on April 29, 2026, Drugs Made In America Acquisition Corp., a Cayman Islands exempted company, entered into a Definitive Merger Agreement with Power Analytics Global Corp, a Delaware corporation engaged in the business of artificial intelligence, advanced… Filing
  3. Jul 20, 2026AgreementAmendment to Merger Agreement As previously disclosed, on April 29, 2026, Drugs Made In America Acquisition Corp., a Cayman Islands exempted company, entered into a Definitive Merger Agreement with Power Analytics Global Corp, a Delaware corporation engaged in the business of artificial… Filing
  4. May 5, 2026AgreementDrugs Made In America Acquisition Corp., a Cayman Islands exempted company, entered into a Definitive Merger Agreement with Power Analytics Global Corp, a Delaware corporation engaged in the business of artificial intelligence, advanced analytics and quantum-resistant security solutions. Filing
  5. May 1, 2026AnnouncementIn connection with the shareholders’ vote at the Extraordinary General Meeting, holders of 9,440,230 ordinary shares of the Company exercised their right to redeem such shares for a pro rata portion of the funds held in the Trust Account. Filing
  6. Apr 28, 2026AgreementAs previously disclosed, on November 17, 2025, Drugs Made in America Acquisition Corp. appointed Saleem Elmasri as Chief Financial Officer of the Company and entered into a Master Services Agreement with Titan Advisory Services LLC for the provision of such principal financial and accounting… Filing
  7. Apr 8, 2026AnnouncementDrugs Made in America Acquisition Corp. entered into a letter of intent with Power Analytics Global Corp., a Delaware corporation for a de-SPAC transaction resulting in Target becoming a public company. Filing
  8. Mar 27, 2026AgreementDrugs Made In America Acquisition Corp. issued an interim convertible note to BV Advisory Partners, LLC in the principal amount of $100,000. Filing
  9. Mar 6, 2026AnnouncementAs previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2026, Drugs Made In America Acquisition Corp. announced that, between the completion of the initial public offering for Drugs Made In America Acquisition II Corp., an affiliate of… Filing
  10. Mar 6, 2026LeadershipDepartures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  11. Nov 18, 2025LeadershipGlenn Worman, the Chief Financial Officer and principal financial and accounting officer of Drugs Made In America Acquisition Corp. delivered to the Company a notice of resignation from his position as Chief Financial Officer and principal financial and accounting officer of the Company. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Drugs Made In America Acquisition financials

Questions about Drugs Made In America Acquisition Corp. (DMAA) stock

Who owns the most DMAA stock?

The largest reported owner of Drugs Made In America Acquisition Corp. (DMAA) is Mizuho Securities USA LLC, with 12.1% of the company. In total, 23 funds and institutions reported holding DMAA at the end of Q2 2026, together about 41% of the shares. See the largest owners.

Are DMAA insiders buying or selling?

No DMAA insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in DMAA?

As of Oct 30, 2026, 85,523 DMAA shares were sold short, 0.4% of the shares outstanding, down 4.0% from the report before. At the average daily volume of 17,289 shares, buying them all back would take about 5.0 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.